Efficacy of a polyherbal formulation and life style modification in the management of yakritodar w.s.r to NAFLD - NI

Government of West Bengal0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

暂无简介。

•1.Pain in the upper and epigastric region/pain in the right upper quadrant, fullness of abdomen, feeling of nausea and vomiting, loss of appetite, constipation etc.
•2.Elevated liver enzymes i.e. SGPT more than 1.5 times the normal value.
•3.USG evidence of hepatomegaly with fatty changes in liver.
•4. NAFLD Fibrosis score (NFS) range (less than -1.455 to 0.676).
•5.Diagnosed NAFLD and referred from other outpatient departments
•6. Patients who agreed to follow the study protocol and give constant for clinical trial.

•1.Patient below 18 years and above 65 years.
•2.Patient who are not willing to come under trial or give consent.
•3.NAFLD Fibrosis score (NFS) range (more or equal to 0.676).
•4. Alcoholic steatohepatitis
•5. Alcoholic fatty liver (typically, a threshold of more than 20g/day for woman and more than 30g/day for men), ALT more or equal to 120 IU/L, total parental nutrition
•6. Liver cirrhosis/fibrosis, heart or renal failure.
•7. Underwent liver transplantation, gastrointestinal surgery.
•8.Vascular diseases of the liver, allergy, liver mass.
•9. H/o or presence of Type 1 DM
•10.Presence of any other form of chronic liver disease
•11.Hepatitis (A, B, C, D, E) positive patients
•12.Wilsons disease or metabolic liver disease
•13.Polycystic liver disease
•14.Cystic fibrosis of liver
•15.Non Alcoholic cirrhosis
•16.Auto immune hepatitis
•17.Primary and secondary Hepatic cellular Carcinoma (HCC)
•19.Gilbert disease
•20.alpha 1 antitrypsin deficiency
•21.Pregnant and lactating mother
•22.History of heart attack or stroke
•23.Mentally disabled patients

发起方